Mitochondrial uncoupler
BAM15
BAM15 after one dose: 50% at ~1 h, 25% at 2 h, 12.5% at 3 h.
Drawn from the half-life in the app's model, ~1 h. The model's figures
- Compound
- BAM15
- Symbol
- BAM
- Family
- Metabolic and mitochondrial peptides
- Parts
- 13
- References
- 5
- Checked
- Last reviewed . Sources are listed below.
Overview
BAM15 is a small molecule that Kenwood and colleagues identified by screening a chemical library for mitochondrial uncouplers that lack off-target activity at the plasma membrane (Molecular Metabolism, 2014).3 The paper describes mitochondrial uncouplers as "lipophilic weak acids that transport protons into the mitochondrial matrix via a pathway that is independent of ATP synthase, thereby uncoupling nutrient oxidation from ATP production".3
No controlled trial of BAM15 in people was identified in PubMed or ClinicalTrials.gov, and no DailyMed drug label for BAM15 was identified. The efficacy and safety findings summarised below come from cell experiments and mice. The app grades the evidence as emerging and states in its own note that all efficacy evidence is mouse.
Each of the four research papers cited here reports an author tie to BAM15 or to uncoupler development. Kenwood and colleagues state that "BMK and KLH are co-inventors on a patent application involving BAM15".3 Alexopoulos and colleagues state that three authors "have a financial interest in Continuum Biosciences, a company that develops mitochondrial uncouplers as therapeutics".1 Axelrod and colleagues state that one author "is an equity holder in Continuum Biosciences, a company that has commercial interest in mitochondrial uncouplers as therapeutics".2 Quinlan and colleagues state that two authors "are inventors of small molecule mitochondrial uncouplers that are licensed to Uncoupler Biosciences, Inc."4
How it works
Sources in this part
Kenwood and colleagues compared BAM15 with FCCP, which they describe as "an uncoupler of equal potency", and report that BAM15 "stimulates a higher maximum rate of mitochondrial respiration and is less cytotoxic".3 In whole-cell recordings (N=7–9 cells per condition), "BAM15 elicited no appreciable change in current in the same cells" in which FCCP produced an inward current, and under current clamp "FCCP caused reversible and repeatable plasma membrane depolarization, whereas BAM15 had no effect".3 The same paper says that "the most widely used protonophore uncouplers" including 2,4-dinitrophenol (DNP) "have off-target activity at other membranes that lead to a range of undesired effects including plasma membrane depolarization, mitochondrial inhibition, and cytotoxicity", and that these properties "result in a narrow therapeutic index that limits their usefulness in the clinic".3 The authors write that why BAM15 acts on mitochondria but not the plasma membrane "is unclear".3 In mouse liver cells, Alexopoulos and colleagues report BAM15 as "~7-fold more potent than DNP for stimulating oxygen consumption rate (OCR)", with average EC50 values of 1.4 μM against 10.1 μM.1 The app's note places BAM15 in the same hyperthermia risk class as DNP because every protonophore releases heat while dissipating the proton gradient, and says the absence of a temperature rise in mice has never been tested in a human. Axelrod and colleagues suggest that the ability of BAM15 to raise energy expenditure without hyperthermia in mice "may be attributable to extended respiratory activity in conjunction with improved cellular tolerability relative to previous generation molecules".2
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~1 h
- Bioavailability
- 40%
- Typical dose
- 5–20 mg/day
- Route
- Oral
- Time to peak
- ~0.75 h
The app's half-life, bioavailability and time to peak are modelling choices rather than measured human values, and none of the cited papers reports human pharmacokinetics. The mouse figures below come from oral gavage in one paper and from dietary dosing in another.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~1 h | Mouse: 1.7 h after oral gavage of 10 mg/kg (Alexopoulos); about 3 h during dietary dosing at 0.1% w/w (Axelrod). Four BAM15 derivatives in mice: 15 min, 27 min, 1.8 h and 0.59 h (Quinlan). No human value.1,2,4 |
| Bioavailability | 40% | Mouse: 67% oral bioavailability from a dose-normalised area under the curve (1 mg/kg intravenous, n = 4; 10 mg/kg oral gavage, n = 3) (Alexopoulos). No human value.1 |
| Time to peak | ~0.75 h | The text of the cited papers gives no plasma time to peak. After 100 mg/kg by gavage in mice, raised oxygen use "gradually returned to baseline ~3 h post gavage" (Alexopoulos).1 |
| Plasma exposure | Not listed | Mouse: average Cmax of 8.2 µM after 10 mg/kg by gavage (Alexopoulos); 5 to 10 µM through the dark period on 0.1% w/w in diet (Alexopoulos); peak serum concentration of about 5 μM (Axelrod).1,2 |
Both mouse efficacy papers dosed the compound in the diet for long-term studies. Alexopoulos and colleagues write that "BAM15 has low aqueous solubility and a half-life of 1.7 h; therefore, it was admixed in food for long-term treatment studies".1 Axelrod and colleagues write that "BAM15 is a highly lipophilic compound, and as a result, it is not suitable for chronic injection in vivo".2 The two labs differ on where the compound goes: Alexopoulos reports "primary distribution to the liver" after gavage of 50 mg/kg, and Axelrod reports "primary distribution into adipose tissue depots and to lesser extent, liver, heart, and kidneys" during dietary dosing.1,2 Axelrod and colleagues also write that "despite a relatively rapid rate of disappearance from the circulation and tissues, BAM15 remains highly active in the mitochondria".2 Kenwood and colleagues state that "future pharmacokinetic analysis will be required to determine if BAM15 is suitable for long-term treatment of pathologies that require constant exposure such as progressive metabolic disorders".3 The app's note gives mouse half-lives of 15 to 27 minutes for close analogs; the Quinlan table lists 15 min, 27 min, 1.8 h and 0.59 h for four derivatives, and the app's note does not name which analogs it means.4
Human studies
No controlled trial of BAM15 in people was identified in PubMed or ClinicalTrials.gov, so no human results are reported here. The table lists three studies, which used cultured cells and mice, and its People column describes animals.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Kenwood and colleagues, Molecular Metabolism 20143 | Cell recordings and a mouse kidney injury model; two authors are co-inventors on a patent application3 | None: cultured cells (N=7–9 per condition) and male C57BL/6 mice (N = 3-6 per group)3 | Single intraperitoneal bolus of 1 or 5 mg/kg given 1 h before 26 min of bilateral renal ischemia3 | BAM15 did not depolarize the plasma membrane in cells; mice given BAM15 had lower plasma creatinine at 24 and 48 h3 |
| Alexopoulos and colleagues, Nature Communications 20201 | Mouse prevention (8 days) and reversal (9 weeks) studies with clamp; three authors have a financial interest in Continuum Biosciences1 | Male C57BL/6J mice on a western diet (n = 6 to 12 per group in prevention)1 | 0.05%, 0.10% or 0.15% w/w in diet for 8 days; 0.1% w/w for 5 weeks in the reversal study1 | Same calories as controls with 15% less body weight, almost entirely fat, and no difference in fat-free lean mass; ALT, AST, GLDH and creatine kinase unaffected1 |
| Axelrod and colleagues, EMBO Molecular Medicine 20202 | Randomised mouse study (3 weeks) and a calorie-restriction comparison (2 weeks); one author is an equity holder in Continuum Biosciences2 | Male diet-induced obese C57BL/6J mice (N = 32 in the 3-week study)2 | 0.1% w/w in a 60% high-fat diet, about 85 mg/kg/day by food consumption2 | Reduced fat mass with no change in lean mass from baseline; food intake unaffected until day 20; body temperature unchanged2 |
Sources in this part
Deeper analysis: Alexopoulos and colleagues, Nature Communications 2020
Alexopoulos and colleagues, with the first author at the University of New South Wales, report a set of experiments in male C57BL/6J mice on a western diet.1 In the prevention experiment, "BAM15 had a dose-dependent effect on fat mass": 0.05% w/w limited fat mass gain by more than half, and 0.10% to 0.15% w/w stopped it, without changes in fat-free lean mass or food intake, over 8 days.1 In the reversal experiment, mice were fed the diet for 4 weeks, which "increased fat mass by threefold relative to their pre-diet starting point", and were then randomised to the diet with or without 0.1% BAM15 for 5 weeks.1 Faecal triglyceride, non-esterified fatty acid and cholesterol content "were not statistically different" between the groups, which the authors take to show that fat loss was not due to lipid malabsorption.1 Mice on 0.1% w/w had "an average 15% increase in oxygen consumption during the dark period" (n = 5 control and n = 6 BAM15 animals).1 In gavage experiments, the 50 mg/kg and 100 mg/kg doses raised oxygen use in the first hour by 30% (p = 0.050 against vehicle) and 50% over baseline.1 Liver respiration rose 54% at 50 mg/kg, while "muscle showed a non-significant trend for increased respiration and adipose tissue depot respiration was unchanged".1 After 6 weeks of treatment, a hyperinsulinemic-euglycemic clamp (n = 9 chow, n = 7 western diet, n = 8 western diet with BAM15) showed that BAM15 "markedly improved whole-body glucose clearance compared with WD control animals by increasing the glucose infusion rate required to maintain euglycemia to levels comparable with chow-fed mice".1 The clamp also had secondary and null results: suppression of liver glucose output in BAM15 animals was "an intermediate phenotype that was not statistically different from either group", and "BAM15 treatment had no effect on heart glucose uptake".1 Liver ATP was not altered, and the authors report no change in AMPK phosphorylation in liver tissue.1 On safety, blood markers of liver, muscle and heart tissue health (ALT, AST, GLDH, creatine kinase) were "not affected"; BAM15-treated mice had "normal creatinine levels and mildly (22%) elevated BUN levels that remained within the normal reference range for male C57BL/6 J mice", and plasma triglycerides were "decreased by 29%".1 Gavage doses were not raised above 200 mg/kg because preparing the compound became impractical and "transient behavioural signs of lethargy were observed that were not possible to distinguish drug effects from delivery of paste to the stomach".1 The authors name two limitations: "One limitation of BAM15 is low aqueous solubility" and "Another limitation of BAM15 is a 1.7 h half-life".1 Funding listed includes university funds, Australian and US grants, and "Continuum Biosciences to K.L.H. and W.L.S.", the company in which three authors report a financial interest.1
Deeper analysis: Axelrod and colleagues, EMBO Molecular Medicine 2020
Axelrod and colleagues randomised 10-week-old male diet-induced obese C57BL/6J mice to 3 weeks of a 60% high-fat diet with or without 0.1% w/w BAM15, in a design with a blinded biostatistician allocating the animals.2 Mice ate about 85 mg/kg/day, and body weight was lower than in controls from day 9; the paper adds that BAM15 "did not affect daily (Fig EV2D and E) or cumulative food intake until day 20", when the body weight difference was 7.5 g.2 Fat mass fell with "no change in lean mass compared with baseline", and neither a single intraperitoneal injection (0.1, 0.5 or 1 mg/kg) nor chronic oral dosing "altered body temperature".2 In a separate 2-week experiment (control N = 7, BAM15 and calorie-restricted N = 8) with body weight matched to a calorie-restricted group, BAM15 animals "displayed greater reductions in fat mass relative to CR" and "improved glucose clearance relative to both CTRL and CR".2 In that same experiment, the BAM15 group "displayed reduced lean mass relative to CTRL but increased relative to CR", so lean mass was not unchanged in every comparison.2 The paper reports a reduction of about 75% in liver lipid accumulation and, in the mice that were studied, no deleterious muscle effects; it also states that the compound "did not result in the histopathological features present in previous generation protonophores".2 The same paper states that it determined in vitro that AMPK is activated in response to BAM15 and is required to sustain its mitochondrial function, and that the metabolic action in vivo was largely localised to white adipose tissue.2 The stated limitations are that the compound was dosed in the diet so "the time and dosing of each animal varied by ad libitum food intake", and that "the use of male C57BL/6J mice did not allow for consideration of sex as a biological variable".2 Funding includes "National Institutes of Health grants DK108089 (JPK)" among others, and one author is an equity holder in Continuum Biosciences.2 Two authors of this paper (Alexopoulos SJ and Hoehn KL) also appear on the Alexopoulos author list, so the two mouse papers are not fully independent of each other.2,1
Deeper analysis: Kenwood and colleagues, Molecular Metabolism 2014
Kenwood and colleagues screened a small molecule chemical library through a series of cell-based filters for oxygen consumption, reactive oxygen species, dynamic range and plasma membrane electrophysiology.3 In whole-cell recordings at 1 µM and 10 µM, FCCP produced a dose-dependent inward current and depolarization, and BAM15 did not; "BAM15-treated cells were more viable than FCCP-treated cells when administered across a broad dosing range up to 50 μM".3 In the in vivo test, a single intraperitoneal bolus of 1 or 5 mg/kg given 1 h before 26 min of bilateral renal ischemia in male 8-week-old mice (N = 3-6 per group) gave lower plasma creatinine at 24 and 48 h, with less tubular necrosis.3 The authors describe the result as showing that BAM15 "is bioactive in vivo", and say that the pharmacokinetic work needed for long-term use remains to be done.3 The paper lists grants from the US National Institutes of Health institutes, and its conflict statement says two authors are co-inventors on a patent application involving BAM15.3
Doses reported in studies and on labels
Sources in this part
No drug label for BAM15 was identified, and the app's note states that its dose range is not human-established and is not derived from any trial. The app lists 5–20 mg/day and states that the range "is NOT human-established and is not derived from any trial". The doses below were given to mice.
| Reference | Dose and route in mice | Setting |
|---|---|---|
| Alexopoulos 20201 | 10, 50 or 100 mg/kg by oral gavage (n = 3 to 4 per group) | Oxygen consumption: 50 and 100 mg/kg raised oxygen use in the first hour; 10 mg/kg had no detectable effect |
| Alexopoulos 20201 | Up to 200 mg/kg by oral gavage (n = 6) | Body temperature over 4 h: no effect; gavage not raised further |
| Alexopoulos 20201 | 0.05%, 0.10% or 0.15% w/w in diet for 8 days; 0.1% w/w for 5 weeks | Fat mass prevention and reversal studies |
| Axelrod 20202 | 0.1% w/w in diet for 3 weeks, about 85 mg/kg/day | Diet-induced obesity study (N = 32) |
| Axelrod 20202 | Single intraperitoneal injection of 0.1, 0.5 or 1 mg/kg | Body temperature before and after injection (N = 11 per group) |
| Kenwood 20143 | Single intraperitoneal bolus of 1 or 5 mg/kg | Kidney ischemia-reperfusion model (N = 3-6 per group) |
The app's note gives mouse dietary concentrations of 0.15 to 0.2 percent of chow by weight; the two papers above report 0.05% to 0.15% w/w and 0.1% w/w.1,2 For comparison, Alexopoulos and colleagues report that DNP "resulted in a no observed adverse effect level of 25 mg/kg" in mice.1
Side effects reported
Sources in this part
No trial of BAM15 in people was identified in PubMed or ClinicalTrials.gov, so no human adverse event reports were found in the searches run. In mice, Alexopoulos and colleagues state that "doses up to 200 mg/kg had no effect on body temperature", and Axelrod and colleagues report that neither an acute injection nor chronic oral dosing "altered body temperature".1,2 Alexopoulos and colleagues observed "transient behavioural signs of lethargy" at the highest gavage preparations, which they could not separate from the effect of delivering a thick paste to the stomach.1 The same paper reports plasma urea nitrogen "mildly (22%) elevated" but within the normal range for the mouse strain, and lower plasma triglycerides.1 Axelrod and colleagues report that body weight was lower in the BAM15 group than in controls from day 9, and that BAM15 "did not affect daily (Fig EV2D and E) or cumulative food intake until day 20", when the mean body weight difference was 7.5 g.2 The app's note places BAM15 in the same hyperthermia risk class as DNP and says that the lack of a temperature rise in mice has never been tested in a human.
Bloodwork and markers
Sources in this part
The app lists liver enzymes, blood glucose, heart rate and body weight as markers to monitor. In mice, Alexopoulos and colleagues report that ALT, AST, GLDH and creatine kinase "were not affected by BAM15 treatment".1 They also report a dose-dependent decrease in fasting blood glucose in the prevention study, and Axelrod and colleagues report lower fasting plasma glucose and insulin after 3 weeks, while fasting glucose did not differ between groups in their 2-week comparison with calorie restriction.1,2 Body weight in the 9-week reversal study was 15% lower with BAM15 than with the western diet alone, on the same calories.1 These are mouse findings; no trial of BAM15 in people was identified in the searches run.
Regulatory and anti-doping status
Sources in this part
The World Anti-Doping Agency's 2026 Prohibited List names BAM15 in class S4.4.1, as an example of activators of the AMP-activated protein kinase (AMPK).5 Class S4 is listed as prohibited at all times, in and out of competition, and the list states that classes S4.3 and S4.4 are non-Specified Substances.5 The same list's S0 class on non-approved substances names 2,4-dinitrophenol (DNP) among its examples.5 No DailyMed label for BAM15 was identified, and no regulator approval document was located in the searches run.
What is not known
Sources in this part
Human pharmacokinetics, safety and efficacy of BAM15 were not identified in the searches run, so the app's half-life, bioavailability, time to peak and dose range have no human measurement behind them. Whether the absence of a temperature rise seen in mice holds in people is, in the app's words, untested. Both mouse efficacy papers used male mice and diet-based dosing, and Axelrod and colleagues state that male-only work "did not allow for consideration of sex as a biological variable".2 The app's note describes mouse findings as consistent across independent labs; the two efficacy papers share authors, and each includes an author with a commercial interest in uncouplers.1,2 Where the compound distributes (liver in one paper, adipose tissue in the other) and how exposure relates to effect over time are reported differently across the two mouse papers.1,2
Frequently asked questions
What is the half-life of BAM15?
Has BAM15 been tested in people?
No trial of BAM15 in people was identified in PubMed or ClinicalTrials.gov on 16 November 2026. The app's own note says all efficacy evidence is mouse.
Is BAM15 banned by WADA?
The 2026 WADA Prohibited List names BAM15 in class S4.4.1 (activators of the AMP-activated protein kinase), which is prohibited at all times.5
Is BAM15 approved by the FDA?
No DailyMed label for BAM15 was identified in a search on 16 November 2026.
What is the bioavailability of BAM15?
The app lists 40%, and the cited mouse paper reports 67% oral bioavailability in mice.1
What is BAM15?
BAM15 is a mitochondrial protonophore uncoupler identified in a chemical library screen, and the screen was designed to find uncouplers that lack activity at the plasma membrane.3
How does BAM15 differ from DNP?
More in Metabolic and mitochondrial peptides
References
- Alexopoulos SJ, et al. Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nat Commun 2020. PMID 32409697
- Axelrod CL, et al. BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control. EMBO Mol Med 2020. PMID 32519812
- Kenwood BM, et al. Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane. Mol Metab 2014. PMID 24634817
- Quinlan JE, et al. Unsymmetric hydroxylamine and hydrazine BAM15 derivatives as potent mitochondrial uncouplers. Bioorg Med Chem 2025. PMID 39740573
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list